Prediction of inactive disease and relapse in oligoarticular juvenile idiopathic arthritis.


Journal

Modern rheumatology
ISSN: 1439-7609
Titre abrégé: Mod Rheumatol
Pays: England
ID NLM: 100959226

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 15 10 2020
medline: 8 10 2021
entrez: 14 10 2020
Statut: ppublish

Résumé

The aim of this study is to describe clinical features of patients with oligoarticular juvenile idiopathic arthritis (JIA) who achieved inactive disease at 3rd month and also to determine the predictors of relapse and extended course. In the cohort study, 88 patients with oligoarticular JIA were retrospectively analyzed. The demographic data, clinical features, medications, relapse rates were recorded. Juvenile Arthritis Disease Activity Score (JADAS) and American College of Rheumatology Pediatric criteria were used to measure disease activity and treatment response at 3, 6 and 12 months. Fifty-nine (67%) patients were females and the mean age at diagnosis was 7.9 ± 4.3 years. The odds of achieving inactive disease (JADAS ≤1) at 3rd month were increased by a lower JADAS27 score at admission. Forty-one (48.8%) of 84 patients relapsed. Ankle involvement at onset, high JADAS27 score at admission, increased ESR at admission and presence of synovial hypertrophy in imaging were risk factors for occurrence of relapse. Our results show that a significant proportion of oligoarticular JIA patients relapse after inactive period. JADAS is a useful tool to guide the treatment decisions of patients who may be at risk of high disease activity and relapse.

Identifiants

pubmed: 33050742
doi: 10.1080/14397595.2020.1836788
doi:

Substances chimiques

Antirheumatic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1025-1030

Auteurs

Müge Sezer (M)

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Fatma Aydın (F)

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Tuba Kurt (T)

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Nilüfer Tekgöz (N)

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Zahide Ekici Tekin (ZE)

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Cüneyt Karagöl (C)

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Nilgün Çakar (N)

Department of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, Turkey.

Banu Acar (B)

Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH